EPICS Therapeutics
EPICS is a drug discovery and development company for small molecule drugs targeting RNA epigenetic mecanisms of cancer
EPICS is a drug discovery and development company for small molecule drugs targeting RNA epigenetic mecanisms of cancer
Epic Therapeutics is a biopharmaceutical startup based in Belgium, founded in 2018. The company is focused on developing small molecule drugs targeting RNA epigenetic mechanisms involved in cancer. Its mission is to address unmet medical needs in oncology by inventing novel clinical agents. The recent €7.20M Seed Round investment on 24 May 2018, led by S.R.I.W., signifies investor confidence in the potential of EPICS's innovative approach. The company's ability to balance risk and reward in their development and partnership strategies demonstrates a calculated approach to product development. With a clear focus on high value-added endpoints, EPICS is poised to make significant contributions to the field of cancer treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €7.20M | 1 | S.R.I.W. | 24 May 2018 |
No recent news or press coverage available for EPICS Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
